262 related articles for article (PubMed ID: 23049538)
1. Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Stravodimou A; Mazzoccoli G; Voutsadakis IA
PPAR Res; 2012; 2012():367450. PubMed ID: 23049538
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator activated receptor-γ and the ubiquitin-proteasome system in colorectal cancer.
Voutsadakis IA
World J Gastrointest Oncol; 2010 May; 2(5):235-41. PubMed ID: 21160623
[TBL] [Abstract][Full Text] [Related]
3. The PTB-Associated Splicing Factor/Peroxisome Proliferator-Activated Receptor Gamma Axis Regulates Autophagosome Formation in Human Pancreatic Cancer Cells.
Tsukahara T; Haniu H; Matsuda Y
Biores Open Access; 2015; 4(1):319-25. PubMed ID: 26309807
[TBL] [Abstract][Full Text] [Related]
4. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
5. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo.
Itami A; Watanabe G; Shimada Y; Hashimoto Y; Kawamura J; Kato M; Hosotani R; Imamura M
Int J Cancer; 2001 Nov; 94(3):370-6. PubMed ID: 11745416
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
Kristiansen G; Jacob J; Buckendahl AC; Grützmann R; Alldinger I; Sipos B; Klöppel G; Bahra M; Langrehr JM; Neuhaus P; Dietel M; Pilarsky C
Clin Cancer Res; 2006 Nov; 12(21):6444-51. PubMed ID: 17085658
[TBL] [Abstract][Full Text] [Related]
8. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.
Bren-Mattison Y; Meyer AM; Van Putten V; Li H; Kuhn K; Stearman R; Weiser-Evans M; Winn RA; Heasley LE; Nemenoff RA
Mol Pharmacol; 2008 Mar; 73(3):709-17. PubMed ID: 18055759
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
Voutsadakis IA
J Cell Mol Med; 2007; 11(2):252-85. PubMed ID: 17488476
[TBL] [Abstract][Full Text] [Related]
11. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
12. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells.
Dubois M; Pattou F; Kerr-Conte J; Gmyr V; Vandewalle B; Desreumaux P; Auwerx J; Schoonjans K; Lefebvre J
Diabetologia; 2000 Sep; 43(9):1165-9. PubMed ID: 11043863
[TBL] [Abstract][Full Text] [Related]
13. [Pancreatic carcinogenesis. Clinical implications].
Schneider G; Lersch C; Schmid RM
Chirurg; 2003 Mar; 74(3):165-70. PubMed ID: 12647072
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Zhang Y; Luo HY; Liu GL; Wang DS; Wang ZQ; Zeng ZL; Xu RH
Int J Oncol; 2015 Jan; 46(1):175-84. PubMed ID: 25333644
[TBL] [Abstract][Full Text] [Related]
15. Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis.
Qin RY; Fang RL; Gupta MK; Liu ZR; Wang DY; Chang Q; Chen YB
World J Gastroenterol; 2004 Jan; 10(1):132-5. PubMed ID: 14695784
[TBL] [Abstract][Full Text] [Related]
16. Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system.
Genini D; Catapano CV
J Recept Signal Transduct Res; 2006; 26(5-6):679-92. PubMed ID: 17118805
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis.
Vallée A; Lecarpentier Y
Front Immunol; 2018; 9():745. PubMed ID: 29706964
[TBL] [Abstract][Full Text] [Related]
18. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
Dong YW; Wang XP; Wu K
World J Gastroenterol; 2009 Jan; 15(4):441-8. PubMed ID: 19152448
[TBL] [Abstract][Full Text] [Related]
19. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia.
Hahn SA; Schmiegel WH
Digestion; 1998 Aug; 59(5):493-501. PubMed ID: 9705534
[TBL] [Abstract][Full Text] [Related]
20. [Regulatory effects of peroxisome proliferator-activated receptor gamma on the growth of pancreatic carcinoma].
Dong YW; Wang XP; Wu K; Wu LY; Zhang RL
Zhonghua Nei Ke Za Zhi; 2003 Jul; 42(7):479-82. PubMed ID: 12921608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
